Insight

Endometrial Cancer Advances – Dana-Farber Cancer Institute

urogynecology.in

Nov 7, 2024, 15:50

Endometrial Cancer Advances – Dana-Farber Cancer Institute

Dana-Farber Cancer Institute shared a post on LinkedIn:

“For the past decade, new cases of endometrial (uterine) cancer have been on the rise in the United States, making it the leading cause of death among gynecologic cancers. The reasons for the steady rise in diagnoses and an increase in a subset of endometrial cancers known as ‘non-endometrioid’ are unclear.

But what is known is that these cancers have a wide array of genetic abnormalities and are often aggressive. With a decrease in federal research funding, the need for novel therapies is critical.

Despite this, there has been a more promising rise over the last few years: A new generation of drugs and drug combinations that are improving the outlook for patients with the disease.

Dana-Farber scientists are tackling the disease from multiple angles – hormonal therapy, immunotherapy, antibody-drug conjugates, and replication stress – to propel this promising new generation of therapies forward.

Learn more.”

Antibody drug conjugates cancer Dana-Farber Cancer Institute drug combinations endometrial cance genetic abnormalities Gynecologic Cancer hormonal therapy immunotherapy OncoDaily Oncology Replication Stress

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute

FDA Approves Nivolumab and Ipilimumab for First-Line Treatment of Unresectable Hepatocellular Carcinoma Based on CheckMate-9DW Trial